Despite Predominance of Uropathogenic/Extraintestinal Pathotypes Among Travel-acquired Extended-spectrum β-Lactamase–producing Escherichia coli, the Most Commonly Associated Clinical Manifestation Is Travelers’ Diarrhea

• Published in: Clinical infectious diseases Vol. 70; no. 2; pp. 210 - 218
• Main Authors: Kantele, Anu, Lääveri, Tinja, Mero, Sointu, Häkkinen, Inka M K, Kirveskari, Juha, Johnston, Brian D, Johnson, James R
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 02.01.2020
• Subjects: and Commentaries; beta-Lactamases; Diarrhea - epidemiology; Enteropathogenic Escherichia coli; Escherichia coli Infections - epidemiology; Feces; Humans; Travel; ESBL; DEC; extended-spectrum beta-lactamase; travel; ExPEC
• DOI: 10.1093/cid/ciz182
• ISSN: 1058-4838; 1537-6591

Abstract Background One-third of the 100 million travelers to the tropics annually acquire extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae (ESBL-PE), with undefined clinical consequences. Methods Symptoms suggesting Enterobacteriaceae infections were recorded prospectively among 430 Finnish travelers, 90 (21%) of whom acquired ESBL-PE abroad. ESBL-PE isolates underwent polymerase chain reaction–based detection of diarrheagenic Escherichia coli (DEC) pathotypes (enteroaggregative E. coli [EAEC], enteropathogenic E. coli [EPEC], enterotoxigenic E. coli [ETEC], enteroinvasive E. coli, and Shiga toxin–producing E. coli), and extraintestinal pathogenic/uropathogenic E. coli (ExPEC/UPEC). Laboratory-confirmed ESBL-PE infections were surveyed 5 years before and after travel. Results Among the 90 ESBL-PE carriers, manifestations of Enterobacteriaceae infection included travelers’ diarrhea (TD) (75/90 subjects) and urinary tract infection (UTI) (3/90). The carriers had 96 ESBL-producing E. coli isolates, 51% exhibiting a molecular pathotype: 13 (14%) were DEC (10 EAEC, 2 EPEC, 1 ETEC) (12 associated with TD) and 39 (41%) ExPEC/UPEC (none associated with UTI). Of ESBL-PE, 3 (3%) were ExPEC/UPEC-EAEC hybrids (2 associated with diarrhea, none with UTI). Potential ESBL-PE infections were detected in 15 of 90 subjects (17%). The 10-year medical record survey identified 4 laboratory-confirmed ESBL-PE infections among the 430 travelers, all in subjects who screened ESBL-PE negative after returning home from their index journeys but had traveled abroad before their infection episodes. Conclusions Half of all travel-acquired ESBL-producing E. coli strains qualified molecularly as pathogens. Extraintestinal and uropathogenic pathotypes outnumbered enteric pathotypes (41% vs 14%), yet the latter correlated more closely with symptomatic infection (0% vs 92%). Despite more ESBL-PE strains qualifying as ExPEC/UPEC than DEC, travel-acquired ESBL-PE are more often associated with TD than UTI. Of subjects with travel-acquired extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL-PE), 87% contracted potential Enterobacteriaceae infections, mostly diarrhea. Although ESBL-PE isolates more commonly displayed extraintestinal/uropathogenic than enteric pathotypes, hosts more commonly had travelers’ diarrhea than urinary tract infection.